AR050293A1 - Polipeptidos de interleuquina-15 mutante - Google Patents

Polipeptidos de interleuquina-15 mutante

Info

Publication number
AR050293A1
AR050293A1 ARP050103371A ARP050103371A AR050293A1 AR 050293 A1 AR050293 A1 AR 050293A1 AR P050103371 A ARP050103371 A AR P050103371A AR P050103371 A ARP050103371 A AR P050103371A AR 050293 A1 AR050293 A1 AR 050293A1
Authority
AR
Argentina
Prior art keywords
mutant
polypeptides
polypeptide
interleuquine
glutamine residues
Prior art date
Application number
ARP050103371A
Other languages
English (en)
Original Assignee
Moll Tomas
Zheng Xin Xiao
Strom Terry B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moll Tomas, Zheng Xin Xiao, Strom Terry B filed Critical Moll Tomas
Publication of AR050293A1 publication Critical patent/AR050293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composiciones que incluyen dichos polipéptidos, así como método para obtenerlos entre otros, el polipéptido IL-15 mutante está unido a un polipéptido heterologo. Usos de los polipéptidos IL-14 mutantes, por ejemplo, en la supresion de respuestas inmunes. Reivindicacion 1: Un polipéptido de interleuquina-15 (IL-15) mutante, caracterizado porque comprende una IL-15 natural que contiene una mutacion por supresion de uno o más de los primeros 48 residuos de aminoácidos de la secuencia senal y una mutacion por sustitucion de uno de los residuos de glutamina correspondiente a los residuos de glutamina en las posiciones 101 y 108 de la SEQ ID Ns: 1.
ARP050103371A 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante AR050293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60104204P 2004-08-11 2004-08-11
US60047804P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
AR050293A1 true AR050293A1 (es) 2006-10-11

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103371A AR050293A1 (es) 2004-08-11 2005-08-11 Polipeptidos de interleuquina-15 mutante
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP050103369A AR050693A1 (es) 2004-08-11 2005-08-11 Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.

Country Status (4)

Country Link
US (2) US20060057102A1 (es)
AR (2) AR050293A1 (es)
TW (2) TW200613552A (es)
WO (2) WO2006020849A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
AR050293A1 (es) * 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CA2636111C (en) 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
AU2010253863B2 (en) * 2009-05-28 2016-01-28 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
MX2017004838A (es) * 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
JP6800219B2 (ja) * 2015-09-16 2020-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
MX2019007357A (es) * 2016-12-21 2019-09-05 Cephalon Inc Anticuerpos que se unen especificamente a il-15 humana y usos de estos.
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3060410A1 (en) 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
EP3758729B1 (en) 2018-02-26 2024-11-06 Synthorx, Inc. Il-15 conjugates and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
MX2021014189A (es) 2019-05-20 2022-01-06 Cytune Pharma Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
MX2023015400A (es) 2021-06-23 2024-03-07 Cytune Pharma Variantes de interleucina 15.
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
JP2001502521A (ja) * 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
AR050293A1 (es) * 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15

Also Published As

Publication number Publication date
US20060057102A1 (en) 2006-03-16
AR050693A1 (es) 2006-11-15
US20060057680A1 (en) 2006-03-16
WO2006017853A2 (en) 2006-02-16
WO2006020849A2 (en) 2006-02-23
TW200613552A (en) 2006-05-01
WO2006020849A3 (en) 2006-10-05
TW200619227A (en) 2006-06-16
WO2006017853A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
AR050293A1 (es) Polipeptidos de interleuquina-15 mutante
MX2020009824A (es) Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
AR114445A1 (es) Conjugados de il-15, y sus usos
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR079338A1 (es) Variantes de proteasa de bacillus y acidos nucleicos que codifican dichas variantes
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
AR023020A1 (es) Variante de proteasa serina, composiciones para cuidado personal y para limpieza y gen de proteasa serina mutante que la codifica la variante
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
DK1654355T3 (da) Pseudomonas polypeptidvarianter med ikke-maltogen exoamylaseaktivitet og deres anvendelse til fremstilling af fødevarer
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
CY1111411T1 (el) Αναλογα του παρομοιου-με-την-γλυκαγονη-πεπτιδιου-2(glp-2)
ATE119941T1 (de) Subtilisin-analoge.
DK1237930T3 (da) Kimære amyloid-beta-peptider
PE20090711A1 (es) Region constante de anticuerpo mutante
RU2011144134A (ru) Композиции и способы, включающие варианты альфа-амилазы с измененными свойствами
PE20090682A1 (es) Secuencias peptidicas y composiciones
PE20140173A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
ATE533845T1 (de) Eukaryotische signalsequenzen zur polypeptid- expression und polypeptid-anzeigebibliotheken
MX2022008060A (es) Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.
DE602006018308D1 (de) Chimärer impfstoff für haemophilus influenzae-induzierte infektion
WO2021216743A3 (en) Coronavirus vaccines, compositions, and methods related thereto
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität

Legal Events

Date Code Title Description
FA Abandonment or withdrawal